jondoeuk
2 years ago
''NT-125 is an investigational, autologous, fully-individualized, multi-specific TCR therapy targeting neoantigens for the treatment of advanced solid tumors. NT-125 is designed to contain up to five distinct neoantigen-specific TCRs per patient in a single cell product of highly functional engineered T cells, allowing multiple neoantigens presented by HLA class I and HLA class II molecules to be targeted with the goal to create a more impactful TCR therapy for more patients. NT-125 aims to reduce the probability of antigen escape and potentially maximize the depth and durability of clinical responses in a patient population with difficult to treat tumors and high unmet need.'' https://www.biospace.com/article/releases/neogene-therapeutics-announces-approval-of-clinical-trial-application-for-its-first-phase-1-trial-of-novel-fully-individualized-tcr-therapy-to-treat-advanced-solid-tumors/
Also, https://www.businesswire.com/news/home/20220111005172/en/Neogene-Therapeutics-Announces-Exclusive-License-with-the-National-Cancer-Institute-for-a-Portfolio-of-T-Cell-Receptors-TCR-Targeting-KRAS-and-TP53-Mutations-for-the-Treatment-of-Cancer
jondoeuk
2 years ago
By Q4 (GEN-011)
20-24 patients dosed.
Day 57 scans from 14-18 patients.
Up to 10 patients on schedule B3 (TIL-like).
Day 113 scans from 9-11 patients.
Up to 8 patients on schedule B3 (TIL-like).
Tumour mix: NSCLC, SCCHN, UC, and melanoma likely to predominate.
Biomarker data: ctDNA, tumour infiltration, TCR sequencing and proliferation and persistence.
jondoeuk
2 years ago
From this: ''Using high-dimensional analysis of human ACT products, we identified a memory-progenitor CD39-negative stem-like phenotype (CD39-CD69-) associated with complete cancer regression and TIL persistence and a terminally differentiated CD39-positive state (CD39+CD69+) associated with poor TIL persistence.'' https://www.science.org/doi/10.1126/science.abb9847
Also, ''With a median potential follow-up of 89 months, 46 of 48 complete responders in the aPD-1-naïve cohort have ongoing responses after a single treatment and 10-year melanoma-specific survival of 96%.'' https://aacrjournals.org/clincancerres/article-abstract/27/19/5289/671696/Impact-of-Prior-Treatment-on-the-Efficacy-of
Hopefully, a trial testing these double negative TIL in melanoma, as well as other types will be underway soon.
NY1972
2 years ago
Intratumoral CD40 agonist sotigalimab with pembrolizumab induces broad innate and adaptive immune activation in local and distant tumors
There was a robust upregulation of T cells, macrophages, CD8+ T cells, and cytotoxic gene signatures in responders. Additionally, responders had an increase in Th1 gene signatures; an increase in TGF-Γ1 gene expression was also noted. In distant lesions, the same gene signatures were upregulated.
https://acir.org/weekly-digests/2022/april/aacr-annual-meeting-2022#therapies